A Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single dose of brincidofovir administered intravenously in healthy adult subjects

This study is testing a new intravenous (IV) formulation of brincidofovir — a drug previously studied as an oral treatment for viral infections such as adenovirus and cytomegalovirus — to see whether it is safe and tolerable when given by injection. Healthy adult volunteers will receive a single dose and be monitored for any side effects. You may be eligible if: - You are between 18 and 55 years old - You are generally healthy with no significant medical history - You have not smoked or used nicotine products in the past 6 months - Your weight is no greater than 50 kg and your BMI is between 18 and 32 - You are not of child-bearing potential (or you meet specific contraception requirements) You may NOT be eligible if: - You are a woman who could become pregnant - You have participated in another clinical study in the past 30 days - You have had any infection in the past 2 weeks - You have a history of chronic liver disease Talk to your doctor about whether this trial might be right for you.